Telomir shares surge 12.95% premarket as Telomir-1 shows preclinical efficacy against leukemia, expanding oncology profile.

Telomir Pharmaceuticals (NASDAQ:TELO) surged 12.95% in premarket trading following the announcement that its investigational compound Telomir-1 demonstrated dose-dependent cytotoxicity against aggressive human leukemia cells in preclinical studies. The in vitro data, released on November 21, 2025, showed Telomir-1 reduced viable HL60 leukemia cells, expanding the drug’s oncology profile to blood cancers after prior activity in breast, pancreatic, and prostate cancer models. The findings highlighted the compound’s ability to modulate intracellular iron levels and inhibit histone demethylase enzymes, key mechanisms in leukemia progression. CEO Erez Aminov emphasized the compound’s potential to address iron dysregulation and epigenetic silencing, core drivers of aggressive cancers. The resignation of a board member (November 14) was unrelated to the stock’s upward movement. The preclinical results, while non-clinical, signaled therapeutic promise, aligning with the sharp premarket rally.